• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非小细胞肺癌患者程序性死亡配体 1 表达的前瞻性评估：一项初步研究。

Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study.

机构信息

. Pneumologia Interventistica, Divisione di Chirurgia Toracica, Istituto Europeo di Oncologia - IEO - Istituto di Ricovero e Cura a Carattere Scientifico - IRCCS - Milano, Italia.

. Divisione di Anatomia Patologica, Istituto Europeo di Oncologia - IEO - Istituto di Ricovero e Cura a Carattere Scientifico - IRCCS - Milano, Italia.

出版信息

J Bras Pneumol. 2021 Jul 12;47(4):e20200584. doi: 10.36416/1806-3756/e20200584. eCollection 2021.

DOI:10.36416/1806-3756/e20200584
PMID:34259745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8332653/
Abstract

OBJECTIVE

EBUS-TBNA cytological sampling is routinely performed for pathological diagnosis, mediastinal staging, and molecular testing in lung cancer patients. EBUS-TBNA samples are not formally accepted for testing programmed death-ligand 1 (PD-L1) expression. The objective of the study was to compare the feasibility, reproducibility, and accuracy of PD-L1 expression assessment in cytological specimens and histological samples.

METHODS

We prospectively collected histological (transbronchial forceps biopsy) and cytological (EBUS-TBNA) samples from peribronchial neoplastic lesions during an endoscopic procedure at the same target lesion for the pathological diagnosis and molecular assessment of stage IV non-small cell lung cancer (NSCLC).

RESULTS

Fifteen patients underwent the procedure. Adequate cytological samples (at least 100 neoplastic cells) were obtained in 12 cases (92.3%). Assessment of PD-L1 expression was similar between histological and cytological samples (agreement rate = 92%). Sensitivity and diagnostic accuracy of EBUS-TBNA cytological specimens were 88.9% and 100%, respectively.

CONCLUSIONS

The evaluation of PD-L1 expression in EBUS-TBNA cytological specimens is feasible and presents good reproducibility when compared with routine histological samples. EBUS-TBNA cytological samples could be used for the assessment of PD-L1 expression in patients with NSCLC as a minimally invasive approach in stage IV NSCLC cancer patients.

摘要

目的

经支气管超声内镜针吸活检（EBUS-TBNA）细胞学采样常用于肺癌患者的病理诊断、纵隔分期和分子检测。EBUS-TBNA 样本未正式用于程序性死亡配体 1（PD-L1）表达检测。本研究的目的是比较细胞学标本和组织学标本中 PD-L1 表达评估的可行性、可重复性和准确性。

方法

我们前瞻性地收集了支气管镜检查过程中支气管周围肿瘤病变的组织学（经支气管活检钳）和细胞学（EBUS-TBNA）样本，用于 IV 期非小细胞肺癌（NSCLC）的病理诊断和分子评估。

结果

15 例患者接受了该操作。12 例（92.3%）获得了足够的细胞学样本（至少 100 个肿瘤细胞）。组织学和细胞学样本的 PD-L1 表达评估结果相似（一致性率=92%）。EBUS-TBNA 细胞学标本的敏感性和诊断准确性分别为 88.9%和 100%。

结论

与常规组织学样本相比，EBUS-TBNA 细胞学标本中 PD-L1 表达的评估是可行的，且具有良好的可重复性。EBUS-TBNA 细胞学样本可用于评估 NSCLC 患者的 PD-L1 表达，作为 IV 期 NSCLC 患者的一种微创方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/de2cffa58a0e/1806-3756-jbpneu-47-04-e20200584-gf4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/313572ac33c6/1806-3756-jbpneu-47-04-e20200584-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/162e1c95011f/1806-3756-jbpneu-47-04-e20200584-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/b09fe8bd3c6c/1806-3756-jbpneu-47-04-e20200584-gf3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/de2cffa58a0e/1806-3756-jbpneu-47-04-e20200584-gf4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/313572ac33c6/1806-3756-jbpneu-47-04-e20200584-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/162e1c95011f/1806-3756-jbpneu-47-04-e20200584-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/b09fe8bd3c6c/1806-3756-jbpneu-47-04-e20200584-gf3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db4a/8332653/de2cffa58a0e/1806-3756-jbpneu-47-04-e20200584-gf4.jpg

相似文献

1
Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study.非小细胞肺癌患者程序性死亡配体 1 表达的前瞻性评估：一项初步研究。
J Bras Pneumol. 2021 Jul 12;47(4):e20200584. doi: 10.36416/1806-3756/e20200584. eCollection 2021.
2
Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.用于非小细胞肺癌诊断和分期的支气管内超声引导下经支气管针吸活检样本的程序性死亡配体1检测
J Bronchology Interv Pulmonol. 2020 Jan;27(1):50-57. doi: 10.1097/LBR.0000000000000623.
3
Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients.经支气管超声引导针吸活检术作为非小细胞肺癌患者程序性死亡配体-1 表达检测的一线淋巴结分期手段的效能。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12459-12468. doi: 10.1007/s00432-023-05039-9. Epub 2023 Jul 14.
4
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.经支气管超声引导经支气管针吸活检术用于非小细胞肺癌 PD-L1 检测。
Chest. 2020 Sep;158(3):1230-1239. doi: 10.1016/j.chest.2020.04.059. Epub 2020 May 16.
5
Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.经支气管超声内镜针吸活检与肺癌切除标本中程序性死亡配体-1 免疫组织化学染色的比较。
Chest. 2018 Oct;154(4):827-837. doi: 10.1016/j.chest.2018.07.017. Epub 2018 Jul 27.
6
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.非小细胞肺癌 EBUS-TBNA 活检标本中 PD-L1 表达和拷贝数状态的异质性分析：原发和转移部位的比较评估。
Lung Cancer. 2019 Aug;134:202-209. doi: 10.1016/j.lungcan.2019.06.002. Epub 2019 Jun 5.
7
Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.基于 EBUS-TBNA 与组织学标本检测 PD-L1 结果，接受抗 PD-1 治疗的晚期非小细胞肺癌患者的真实世界结局。
Chest. 2021 Aug;160(2):743-753. doi: 10.1016/j.chest.2021.02.053. Epub 2021 Mar 3.
8
Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields.支气管内超声引导经支气管针吸活检术与 PD-L1 检测结果。
Lung. 2024 Jun;202(3):325-330. doi: 10.1007/s00408-024-00692-4. Epub 2024 Apr 18.
9
Diagnostic Accuracy of Slow-Capillary Endobronchial Ultrasound Needle Aspiration in Determining PD-L1 Expression in Non-Small Cell Lung Cancer.慢血流支气管内超声针吸术对非小细胞肺癌 PD-L1 表达检测的诊断准确性。
Adv Respir Med. 2023 Jan 12;91(1):1-8. doi: 10.3390/arm91010001.
10
Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.评估EBUS-TBNA细胞学样本中肺癌生物标志物谱以决定靶向治疗
Scott Med J. 2022 Feb;67(1):18-27. doi: 10.1177/00369330221078995. Epub 2022 Feb 11.

引用本文的文献

1
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): revolutionizing the landscape of lung disease diagnostics.经支气管超声引导下经支气管针吸活检术（EBUS-TBNA）：革新肺部疾病诊断格局。
J Med Ultrason (2001). 2024 Apr;51(2):245-251. doi: 10.1007/s10396-023-01391-y. Epub 2023 Dec 19.
2
Diagnostic Performance and Cell Count of EBUS-TBNA Needle Gauges: A Prospective Trial.EBUS-TBNA针径的诊断性能与细胞计数：一项前瞻性试验。
J Clin Med. 2023 Jun 13;12(12):4033. doi: 10.3390/jcm12124033.
3
New Indications in Thoracic Oncology for Mediastinal Lymph Node Staging Using Endobronchial Ultrasound.

本文引用的文献

1
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.非小细胞肺癌靶向治疗的新兴治疗领域。
Signal Transduct Target Ther. 2019 Dec 17;4:61. doi: 10.1038/s41392-019-0099-9. eCollection 2019.
2
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.2019年肺癌的程序性死亡受体1配体（PD-L1）检测：国际肺癌研究协会（IASLC）病理学委员会的观点
J Thorac Oncol. 2020 Apr;15(4):499-519. doi: 10.1016/j.jtho.2019.12.107. Epub 2019 Dec 20.
3
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
经支气管超声引导下纵隔淋巴结分期在胸部肿瘤学中的新应用
Front Oncol. 2022 Jul 8;12:934986. doi: 10.3389/fonc.2022.934986. eCollection 2022.
4
Effector Memory T Cells and CD45RO+ Regulatory T Cells in Metastatic vs. Non-Metastatic Lymph Nodes in Lung Cancer Patients.肺癌患者转移性与非转移性淋巴结中的效应记忆 T 细胞和 CD45RO+调节性 T 细胞。
Front Immunol. 2022 May 2;13:864497. doi: 10.3389/fimmu.2022.864497. eCollection 2022.
5
Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.近红外光免疫疗法（NIR-PIT）在消化道和呼吸道癌症中的内镜应用
Biomedicines. 2022 Apr 4;10(4):846. doi: 10.3390/biomedicines10040846.
局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
4
The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma.各种细胞学标本制备方法在非小细胞肺癌中进行程序性死亡受体配体1（PD-L1）免疫染色的实用性。
J Am Soc Cytopathol. 2018 Nov-Dec;7(6):324-332. doi: 10.1016/j.jasc.2018.07.005. Epub 2018 Jul 25.
5
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.抗 PD-1/PD-L1 治疗非小细胞肺癌：迈向个体化医学和联合策略。
J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018.
6
Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non-Small Cell Lung Cancer. Systematic Review and Meta-Analysis.经支气管超声引导针吸活检术获取样本用于非小细胞肺癌患者分子分析的充分性：系统评价和荟萃分析。
Ann Am Thorac Soc. 2018 Oct;15(10):1205-1216. doi: 10.1513/AnnalsATS.201801-045OC.
7
Endobronchial Ultrasound Transbronchial Needle Aspiration in Thoracic Diseases: Much More than Mediastinal Staging.经支气管超声引导针吸活检术在胸部疾病中的应用：远不止于纵隔分期
Can Respir J. 2018 Mar 4;2018:4269798. doi: 10.1155/2018/4269798. eCollection 2018.
8
Ten Years' Experience in Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer.早期肺癌机器人辅助胸外科手术的十年经验
Thorac Cardiovasc Surg. 2019 Oct;67(7):564-572. doi: 10.1055/s-0038-1639575. Epub 2018 Apr 1.
9
Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples.非小细胞肺癌中酪氨酸激酶抑制剂获得性耐药：下一代测序在内窥镜超声引导经支气管针吸活检样本中的作用。
Arch Pathol Lab Med. 2018 Apr;142(4):465-473. doi: 10.5858/arpa.2017-0158-RA.
10
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.美国病理学家学会、国际肺癌研究协会和分子病理学会更新的肺癌患者靶向酪氨酸激酶抑制剂治疗选择的分子检测指南。
Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22.